Technical Analysis for EYES - Second Sight Medical Products, Inc.

Grade Last Price % Change Price Change
grade D 0.8251 -0.70% -0.01
EYES closed down 0.7 percent on Tuesday, October 15, 2019, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical EYES trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Crossed Above 200 DMA Bullish -0.70%
Crossed Above 50 DMA Bullish -0.70%
Inside Day Range Contraction -0.70%
200 DMA Resistance Bearish 1.99%
20 DMA Resistance Bearish 1.99%

Older signals for EYES ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Second Sight Medical Products, Inc. was founded in 1998 with a mission to restore vision to the blind. Today, Second Sight’s Argus II retinal prosthesis provides functional vision to patients blinded by outer retinal degenerations such as retinitis pigmentosa. The company’s innovative technology is the only retinal prosthesis approved by the United States FDA and the first device to receive a CE mark in Europe. The company’s transformative prosthetic device allows blind individuals to gain greater independence in their daily lives. Second Sight believes that its award winning technology will serve as a platform to treat nearly all forms of blindness and could be extended to other neurostimulation applications beyond vision restoration. The Argus II system is currently available in the US and Europe and the company is actively pursuing additional geographic markets. With next generation products under development, the company plans to continue developing, manufacturing and marketing its innovative visual prostethics around the world. Second Sight’s US Headquarters are in Sylmar, California. European Headquarters are in Lausanne, Switzerland.
Medicine Biotechnology Emerging Technologies Medical Devices FDA Vision Blindness Retinitis Pigmentosa Biomedical Engineering Neuroprosthetics Neurostimulation
Is EYES a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.77
52 Week Low 0.635
Average Volume 193,092
200-Day Moving Average 0.8285
50-Day Moving Average 0.818
20-Day Moving Average 0.8343
10-Day Moving Average 0.8132
Average True Range 0.0545
ADX 19.11
+DI 21.5467
-DI 14.4301
Chandelier Exit (Long, 3 ATRs ) 0.9565
Chandelier Exit (Short, 3 ATRs ) 0.9135
Upper Bollinger Band 0.9301
Lower Bollinger Band 0.7385
Percent B (%b) 0.45
BandWidth 22.96536
MACD Line -0.0036
MACD Signal Line -0.0032
MACD Histogram -0.0004
Fundamentals Value
Market Cap 46.86 Million
Num Shares 56.8 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -1.16
Price-to-Sales 12.04
Price-to-Book 3.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.87
Resistance 3 (R3) 0.86 0.85 0.86
Resistance 2 (R2) 0.85 0.84 0.85 0.86
Resistance 1 (R1) 0.84 0.83 0.84 0.84 0.85
Pivot Point 0.82 0.82 0.83 0.82 0.82
Support 1 (S1) 0.81 0.81 0.82 0.81 0.80
Support 2 (S2) 0.80 0.81 0.80 0.79
Support 3 (S3) 0.78 0.80 0.79
Support 4 (S4) 0.78